Pegasys Returns To Growth In U.S., But Few Other Reasons To Cheer In Roche's Nine-Month Results

Currency headwinds lead Roche to report a 13% decline in pharmaceutical sales in the first nine months of 2011, although at constant exchange rates, sales grew by 1%.